

Impact of a Clinical Outreach Program on Diabetes Treatment CMS STAR Rating

S. Cutts, S. Mankanji, K. Morgan, S. Leo, H. Mankanji, A. Baratz, S. Talala, C. Fiore
Magellan Rx Management • Newport, RI
AMCP 2015 • San Diego, CA

BACKGROUND

- Both angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) have demonstrated kidney-protective effects in diabetes, and are also effective in treating hypertension (in patients with diabetes and hypertension, therapy should include an ACE-I/ARB, as long as one is tolerated).¹
 - ACE-I (and in some cases, ARBs) have been shown to improve cardiovascular and renal outcomes via effects that are independent of blood-pressure reduction.
 - Blood pressure goal for patients with diabetes is <140/90.²
- The Centers for Medicare and Medicaid Services (CMS) have incorporated appropriate treatment of patients with diabetes and hypertension into their Medicare Part D Health and Drug Plan Quality and Performance Ratings (STAR ratings).³
- To assist payers in improving the quality of care delivered to their beneficiaries, Magellan Rx Management has developed and implemented a Diabetes Treatment Clinical Program designed to specifically address the quality standards incorporated into the CMS Star Rating Measure D10, Diabetes Treatment - Appropriate utilization of ACE-I, ARBs, or direct renin inhibitors (DRI) in patients with diabetes and hypertension.

OBJECTIVE

- To measure the impact of a clinical program on measure D10-the proportion of patients with diabetes and hypertension on ACE-I/ARB/DRI therapy within a regional Medicare health plan.

METHODS

- The Diabetes Treatment Measure population consists of all members who have filled a diabetes and hypertension medication between January and December 2014.
- Members are considered compliant when their hypertension agent is an ACE-I/ARB/DRI and non-compliant when not receiving an ACE-I/ARB/DRI.
 - The treatment rate is calculated by taking the numerator (compliant members) divided by the denominator (compliant + non-compliant members).
- A clinical program was implemented to increase the treatment rate, which was to be accomplished through telephonic outreach by clinical staff to providers, pharmacies, and patients.
- The focus of this outreach was recommending use of an ACE-I/ARB/DRI, when appropriate.

RESULTS

Table 1. Outreach Status of Non-Compliant Members

Status	Member Count	Member Count %
Treatment Measure Population	4,185	100%
Outreach Population	903	22%
Conversions to ACE-I/ARB/DRI	391	43%
Clinical & Non-Clinical Rationale for Non-Compliance	257	29%

Figure 1. Treatment Rate vs. Projected Rate without Conversions




Figure 2. Unsuccessful Reason Types





Figure 3. Treatment Rate Improvements vs. MAPD National Avg.



DISCUSSION

- Between January and December 2014, a Diabetes Treatment Clinical Program utilizing clinical outreach resulted in a treatment rate of 88.1% (4 stars) for a regional Medicare health plan, representing a 4.5% increase compared to the same time period in 2013.
 - 391 resulted in a claim for either an ACE-I/ARB/DRI.
 - 257 resulted in clinical and non-clinical rationale for non-compliance.
- Without successful conversions (members with an ACE-I/ARB/DRI claim after outreach), the treatment rate would have been as low as 75.3% (1 star).
- The most common reasons patients in the Diabetes Treatment population did not receive an ACE-I/ARB/DRI were renal complications (35%), patient was not diabetic or not hypertensive (28%), patient had an allergy/intolerance to the medication (18%), and patient refusal (11%).
- It has been estimated that a cumulative, overall 1-star improvement across all measurements (from 3 to 4) is worth \$50 per member per month.

CONCLUSION

- Clinical outreach to non-compliant members and their associated providers and pharmacies resulted in a 1-star improvement for the Diabetes Treatment Measure and prevented a 2-star decrease.
 - Treatment rate in a health plan utilizing a Diabetes Treatment Clinical Program increased by 4.5% from 2013 to 2014 compared to the national average of 0.8%.
- Many patients did not use ACE/ARB/DRI due to clinically valid reasons. These include renal complications, not having diabetes and/or hypertension, and allergies/intolerance. Clinical interventions focusing on improving this measure should take these situations into account to ensure patients are receiving appropriate medications.

REFERENCES

- Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. *Ann Intern Med* 1993; 118:577.
- James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014; 311:507.
- Medicare 2014 Part C & D Star Rating Technical Notes. Centers for Medicare & Medicaid Services. Updated September 2013.

LIMITATIONS

- The true impact of the Diabetes Treatment Clinical Program may be affected by the following confounders:
 - Overlapping providers for other members resulting in patients entering the measure as compliant due to the outreach (who otherwise would have entered the measure as non-compliant).
 - Members who received a claim for an ACE/ARB/DRI post-outreach who may have received an ACE/ARB/DRI regardless.

DISCLOSURES

- This research was conducted by Magellan Rx Management, Newport, RI, without external funding.